Selank / Semax Nootropic Blend (5mg / 5mg)

Selank — Multi-Pathway Anxiolysis Without GABAergic Inhibition

Selank achieves its anxiolytic and nootropic effects through a uniquely broad mechanism that differs fundamentally from classical benzodiazepines, SSRIs, and traditional anxiolytics — it modulates rather than suppresses neurological activity:

GABAergic Modulation — Positive Allosteric, Not Agonist

• Selank acts as a positive allosteric modulator (PAM) of GABA-A receptors — increasing the binding affinity of endogenous GABA to its receptor without directly activating the receptor itself
• This is a critically important pharmacological distinction from benzodiazepines, which directly bind to their own allosteric site and produce full enhancement regardless of GABA availability — a mechanism that leads to tolerance, dependence, and receptor downregulation
• Selank’s allosteric modulation enhances inhibitory neurotransmission in proportion to endogenous GABA activity — calming hyperactive circuits without silencing normal neuronal communication, which explains the absence of sedation and cognitive impairment seen clinically
• Gene expression studies show Selank modulates 7 GABA-signaling genes directly and induces changes in expression of an additional 45, with a net impact on 52 of 84 tested GABA neurotransmission genes — a broad regulatory signature that includes GABA transporter expression and function, not just receptor affinity
• Selank’s allosteric binding site partially overlaps but does not coincide with the benzodiazepine site: it can block the modulatory activity of diazepam and olanzapine when co-administered, and their combined action is non-additive — an interaction pattern that could be clinically relevant​

Enkephalin Metabolism — Protecting Natural Anxiolytic Neuropeptides

• One of Selank’s most pharmacologically interesting mechanisms involves inhibition of enkephalin-degrading enzymes (enkephalinases) — the proteases that cleave endogenous opioid peptides
• Enkephalins are endogenous pentapeptides with potent anxiolytic and mood-regulating properties, but their extremely short half-life (seconds to minutes) limits their physiological impact during stress
• Under stress, elevated cortisol stimulates increased enkephalinase activity — accelerating the degradation that was already limiting enkephalin lifespan
• Selank inhibits enkephalinase activity, prolonging the availability of naturally occurring enkephalins in the synapse and effectively amplifying the body’s own anxiety-counteracting mechanisms
• This mechanism operates independently of GABAergic modulation, creating a dual-pathway anxiolytic action

Serotonin, Dopamine, and Monoamine Modulation

• Selank influences the concentration and metabolism of monoamine neurotransmitters, particularly serotonin and dopamine
• It modulates serotonin synthesis and turnover in a pattern consistent with antidepressant activity — increasing 5-HT availability in the hippocampus and prefrontal cortex while normalizing hyper-reactive monoamine responses to stress​
• Dopaminergic effects: Selank modulates dopamine system activity in ways that support motivated cognition without hyperactivation — contributing to the “calm focus” reported in clinical use​

BDNF Upregulation

• Like its sister compound Semax, Selank elevates brain-derived neurotrophic factor (BDNF) expression in the hippocampus
• This neurotrophic effect provides a degree of overlap with Semax’s primary mechanism and suggests both compounds support neuroplasticity and long-term structural resilience — though BDNF induction is far more potent and rapid for Semax​

Immunomodulatory Activity

• Selank’s structural origin in tuftsin — a known immunostimulatory tetrapeptide — confers immunomodulatory properties not seen with other anxiolytics
• It modulates the expression of Interleukin-6 (IL-6) and the balance of Th1/Th2 cytokines; this immune activity is relevant to stress-neuroimmune interactions, as chronic stress dysregulates immune function and creates a bidirectional relationship between anxiety and inflammation​
• IL-6’s complex role in neuroinflammation and mood regulation (it is elevated in depression and anxiety) makes Selank’s IL-6 modulation a potentially important additional anxiolytic mechanism

Semax — BDNF-Driven Neuroprotection and Cognitive Activation

Semax operates through a distinct but complementary mechanism centered on rapid neurotrophin induction and multi-system monoaminergic modulation:

BDNF / TrkB Axis — The Primary Mechanism

• Semax’s most well-characterized effect is rapid, pronounced upregulation of BDNF (Brain-Derived Neurotrophic Factor) and its high-affinity receptor TrkB in the hippocampus and cortex
• A single application of Semax (50 μg/kg, intranasal) produces a 1.4-fold increase in BDNF protein levels, accompanied by a 1.6-fold increase in TrkB tyrosine phosphorylation (receptor activation), a 3-fold increase in BDNF exon III mRNA, and a 2-fold increase in TrkB mRNA in rat hippocampus — demonstrating both transcriptional upregulation and accelerated receptor signaling​
• In glial cell cultures, BDNF mRNA increased 8-fold and NGF (Nerve Growth Factor) mRNA increased 5-fold within 30 minutes of Semax exposure — among the most rapid neurotrophin responses ever documented for any pharmacological agent​
• BDNF/TrkB signaling downstream: TrkB autophosphorylation activates Ras-MAPK (neuronal differentiation/survival), PI3K-Akt (anti-apoptosis, protein synthesis), and PLCγ-PKC (synaptic plasticity) — explaining how a single BDNF induction event translates to broad neuroprotection and cognitive enhancement

cAMP/CREB Signaling

• Semax activates cAMP/CREB signaling in neurons — the same second messenger pathway central to memory consolidation, synaptic strengthening, and neuronal survival​
• This cAMP elevation may be mediated through melanocortin receptor interactions (MC3/MC4), as Semax is an ACTH analog and ACTH fragments bind melanocortin receptors that signal through Gαs-adenylyl cyclase-cAMP

Serotonergic Activation

• Semax produces a +25% increase in tissue 5-HIAA (serotonin metabolite) in the striatum 2 hours after administration, and extracellular striatal 5-HIAA increases up to 180% within 1–4 hours​
• This serotonergic activation contributes to Semax’s antidepressant-like and anxiolytic secondary effects, and provides a monoamine basis for the mood elevation and motivation enhancement reported clinically

Dopaminergic Potentiation

• Semax does not directly elevate basal dopamine levels but dramatically potentiates dopamine release in response to stimulation — Semax pre-treatment dramatically enhanced D-amphetamine’s effects on striatal extracellular dopamine and locomotor activity​
• This dopaminergic sensitization underlies Semax’s motivational and drive-enhancing properties without producing baseline dopamine excess or overstimulation​

Cholinergic Modulation

• Semax modulates cholinergic tone — relevant to working memory, attention, and executive function, where acetylcholine is the primary neuromodulatory signal​
• This cholinergic component, combined with BDNF-driven synaptic strengthening and cAMP/CREB memory consolidation, creates a multi-pathway basis for the pro-mnemonic effects documented in clinical studies

Neuroprotective Gene Expression — Scale of Effect

• In rat models of focal cerebral ischemia, Semax modulated the expression of over 1,500 genes in the brain — a transcriptome-wide reprogramming of immune, vascular, and neuroprotective gene expression that exceeds what any single receptor-specific drug could achieve​
• Key upregulated gene clusters include: immune system activation genes (complement, cytokines), vascular growth factors, anti-apoptotic genes, and neurotrophic factor pathway genes — a profile consistent with its Russian registration for stroke neuroprotection

The Synergistic Architecture of the Combination

Selank and Semax were developed by the same research institution, from related structural templates, and their combination is not accidental — they form a deliberately complementary dyad:

The core synergy: Semax sharpens and protects; Selank stabilizes and calms — together producing enhanced cognitive performance without the anxiety amplification that high cognitive activation can sometimes trigger, and anxiolytic relief without the cognitive blunting associated with classical sedating anxiolytics.

Selank Research Evidence

Selank has a genuinely substantive human evidence base by peptide standards — most studies are conducted in Russia, but several are published in peer-reviewed journals in the international literature:

• Generalized Anxiety Disorder (GAD) RCT: Randomized, controlled comparison of Selank (intranasal, 400 μg/day for 14 days) versus medazepam (a benzodiazepine) in 62 patients with GAD and neurasthenia. Selank produced equivalent anxiolytic efficacy (Hamilton Anxiety Rating Scale reduction) with a superior side effect profile — no sedation, no cognitive impairment, no withdrawal effects
• Adjustment Disorder Study: Clinical trial in three age groups (21–34, 35–50+ years, n=153) evaluating Selank in adjustment disorder with anxious features. Significant improvements in anxiety measures and stress resistance scores, with well-tolerated profile across age groups​
• Memory protection (Kolik et al., 2019): Selank (0.3 mg/kg/day, 7 days IP) prevented ethanol-induced memory disturbances and age-related cognitive decline in rats, correlated with BDNF normalization in hippocampus and frontal cortex​
• GABAergic gene expression (Seredenina et al., 2017): Published in Frontiers in Pharmacology — definitive characterization of Selank’s effects on 84 GABA-neurotransmission genes in human IMR-32 neuroblastoma cells; confirmed positive allosteric modulation with broad transcriptional signature
• Immunomodulatory effects: Multiple studies demonstrate Selank’s effects on IL-6, IFN-γ, and T helper cell cytokine balance — validated in both animal models and human subjects​
• No serious adverse events in any published clinical study; no dependence, withdrawal, or tolerance observed

Semax Research Evidence

Semax carries the most substantial human clinical evidence of any compound in this catalog outside of tesamorelin:

• Russian clinical approval (1991–2011): Semax has been in clinical use in Russia since the early 1990s, with formal placement on Russia’s List of Vital and Essential Drugs in 2011 for stroke, TIA, cognitive disorders, peptic ulcers, and optic nerve disease — representing three decades of clinical experience and a large observational safety record
• BDNF mechanism — primary paper (Dolotov et al., 2006): Published in Brain Research — defined the BDNF/TrkB mechanism with quantitative in vivo dose-response data (50 μg/kg intranasal); showed parallel improvements in conditioned avoidance learning, establishing the BDNF-cognition link​
• Serotonergic mechanism (Manchenko et al., 2005): Published in European Neuropsychopharmacology — characterized Semax’s time-course of serotonergic activation (+180% extracellular 5-HIAA within 4 hours) and dopamine-potentiating effects​
• Stroke genomics (Filippenkov et al., 2020): Transcriptome-wide analysis of >1,500 Semax-modulated genes in cerebral ischemia-reperfusion models — characterized the neuroprotective gene expression program at a molecular level​
• Neurotrophin cortex study (Shadrina et al., 2009): Published in Frontiers in Molecular Neuroscience — documented BDNF/NGF mRNA upregulation in cortex of ischemic rats treated with Semax and its fragment PGP​
• Cognitive enhancement in healthy subjects: Russian clinical studies documenting improved learning performance, attention, and working memory in healthy volunteers receiving intranasal Semax — though these are largely in the Russian-language literature​
• Chronic stress protection: Semax normalized BDNF content in brain structures of rats with chronic neonatal stress exposure, reversing stress-induced BDNF depletion that is mechanistically linked to depression​
• ACTH copper complex: Semax contains a histidine residue and binds copper(II) with high affinity — a property that may contribute to its antioxidant and neuroprotective effects beyond direct receptor signaling​

Limitations of the Evidence Base

• The overwhelming majority of published clinical and mechanistic data for both compounds originates from Russian research institutions — primarily the Institute of Molecular Genetics and the V.V. Zakusov Institute of Pharmacology
• No independent replication by Western academic institutions exists for the human clinical trials; the international peer-reviewed literature consists primarily of mechanistic and preclinical studies​
• Route of administration asymmetry: Russian clinical use and all published human trials used intranasal administration — a route with well-characterized high CNS bioavailability for these peptides due to olfactory epithelial transport. Injectable (SC/IM) use lacks published pharmacokinetic or safety characterization for either compound​
• Dose translation: The clinical doses used in Russian trials (intranasal) do not directly translate to injectable doses — pharmacokinetic comparability between routes has not been established for these specific peptides

Regulatory Status — Russia and CIS Countries

Both compounds are approved, registered pharmaceuticals in Russia:

• Semax: On Russia’s List of Vital and Essential Drugs since 2011; available by prescription from PEPTOGEN JSC for stroke, TIA, cognitive disorders, optic nerve disease, and immune support; formulated as 0.1% and 1% intranasal drops
• Selank: Registered pharmaceutical in Russia for generalized anxiety disorder and neurasthenia; available from pharmacies in Russia and Ukraine​
• Both are manufactured by regulated pharmaceutical companies under Russian GMP standards — a significant quality assurance distinction from research chemical supply chains​

Regulatory Status — United States (FDA)

The two compounds have meaningfully different U.S. regulatory positions — an important distinction for your product page:

• Semax: Placed on the FDA Section 503A Category 2 list in September 2023, citing “risk for immunogenicity for certain routes of administration due to potential for aggregation and peptide-related impurities” and “limited safety-related information for proposed routes of administration” — effectively prohibiting compounding pharmacies from preparing injectable Semax for human use​
• Selank acetate (TP-7): Initially placed on Category 2, then removed from Category 2 after FDA received clarifying information from the nominator indicating they intended to nominate a different substance. As of the September 2024 FDA 503A update, Selank is not on Category 2. However, it also does not appear on Category 1 (approved for compounding) — meaning it falls into an unresolved regulatory position where it has not been formally reviewed or approved for compounding
• Both remain unapproved new drugs in the United States for any therapeutic indication; selling or marketing either for human therapeutic use is illegal without IND authorization
• Both are commercially available as research chemicals labeled “not for human use”​

WADA Status

• Neither Semax nor Selank appears on the WADA 2025 or 2026 Prohibited Lists under any category
• Neither falls under S2 (growth hormone/peptide hormones), S0 (unless specifically named as non-approved), or any other explicitly applicable prohibited class
• WADA’s general S0 prohibition on “pharmacological substances not currently approved by any governmental regulatory authority” is technically applicable given their non-approval outside Russia/CIS — however, their Russian pharmaceutical approval may complicate a strict S0 interpretation
• As of early 2026, no doping control test has been published or deployed for either compound by WADA accredited laboratories

Selank Safety

Selank’s safety profile is one of the most favorable in this catalog — supported by three decades of use in Russia and multiple published clinical studies:

• No serious adverse events reported in any published clinical trial
• No sedation: Clinical studies consistently confirm absence of sedative effects — a defining advantage over benzodiazepines​
• No cognitive impairment: Unlike benzodiazepines, which impair memory consolidation and psychomotor performance, Selank produced no cognitive impairment in any published study
• No tolerance or dependence: No tolerance development, physical dependence, or withdrawal syndrome observed in clinical or preclinical studies — mechanistically expected given its allosteric (rather than direct) GABAergic action​
• No respiratory depression: Unlike benzodiazepines and barbiturates, Selank’s allosteric modulation does not produce respiratory depression even at high doses in preclinical models​
• Intranasal adverse effects: Minor nasal mucosal irritation and transient discomfort are the most commonly reported effects with intranasal administration​
• Injectable-specific safety: No published data exists for injectable Selank specifically; this route has not been clinically characterized

Semax Safety

• Three decades of clinical use in Russia with a well-established safety record for intranasal administration
• Most common adverse effects (intranasal): Mild nasal irritation, mucosal discoloration with the 1% formulation (less common with 0.1%); dose-dependent and formulation-dependent​
• Glucose elevation: Occasional modest glucose increases reported in diabetic patients — consistent with Semax’s ACTH structural heritage (ACTH stimulates cortisol which raises blood glucose); warrants caution in diabetics​
• Stimulatory effects: Dopamine-potentiating properties mean Semax can produce mild psychostimulant-like effects at higher doses — insomnia, restlessness, or overstimulation if dosed late in the day; not observed at standard doses with appropriate timing​
• No known addiction potential: Despite dopamine modulation, no compulsive use patterns, tolerance, or dependence have been observed in clinical practice​
• Interaction with amphetamines/stimulants: Semax dramatically potentiates amphetamine-induced dopamine release in preclinical models; co-administration with stimulant drugs is not advisable​
• Injectable safety data: Limited; Semax was placed on FDA Category 2 partly based on immunogenicity concerns for injectable routes — the manufacturing purity and aggregation risks of research chemical injectable Semax are real and uncharacterized​

Synergy and Combination Safety

• Selank’s anxiolytic modulation counterbalances Semax’s mild stimulatory properties — the combination produces focused engagement without restlessness or anxiety, which Semax alone can occasionally trigger at the upper end of doses
• No adverse pharmacokinetic or pharmacodynamic interactions are anticipated — the pathways are largely independent and the combination has a long history of use in Russian clinical practice and among researchers​

The combination is commonly dosed intranasally in the countries where both compounds are approved, with the published safety record applying specifically to that route

Selank

1. Zozulya, A.A., et al. (2018). Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Current Molecular Pharmacology, 11(4), 265–271. 
2. Seredenina, T.S., et al. (2017). GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Frontiers in Pharmacology, 8, 89. 
3. Seredenina, T.S., et al. (2016). Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology, 7, 31. 
4. Kolik, L.G., et al. (2019). Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Cognitive Impairment. Bulletin of Experimental Biology and Medicine, 167(6), 780–784. 
5. Peptide Biologix. Selank: Comprehensive Research Monograph. 
6. Revolution Health & Wellness. (2025). Selank Peptide for Anxiety, Focus & Cognitive Health. 

Semax
7. Dolotov, O.V., et al. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54–60. 
8. Manchenko, D.M., et al. (2005). Semax, an ACTH(4-10) analogue with nootropic properties, activates serotonergic and dopaminergic brain systems in rodents. European Neuropsychopharmacology, 16(6), 484–488. 
9. Shadrina, M.I., et al. (2009). Semax and Pro-Gly-Pro Activate the Transcription of Neurotrophins in Cortex of Rats with Cerebral Ischemia. Frontiers in Molecular Neuroscience. 
10. Core Peptides. (2025). The Neuroprotective and Gastroprotective Potential of Semax. 
11. Swolverine. (2025). Semax Dosing Guide: Protocols, Benefits, and Safety. 

Regulatory
12. U.S. FDA. (2023). Substances in Compounding that May Present Significant Safety Risks (Semax). 
13. U.S. FDA. (2024). 503A Categories Update — Selank acetate (TP-7) removed from Category 2. 
14. World Anti-Doping Agency. 2026 Prohibited List. 
15. Makarov, A.A., et al. (2022). Development of Peptide Biopharmaceuticals in Russia. Pharmaceutics, 14(4), 716.